Wilms tumor 6
disease diseaseOn this page
Also known as Wilms tumor 6WT6Wilms tumor type 6Wilms tumour 6, susceptibility toWilms tumour 6Wilms tumour type 6
Summary
Wilms tumor 6 (MONDO:0014779) is a cancer caused by REST (GenCC Strong), with 1 cohort gene (1 CIViC-evidence somatic driver; 58 ClinVar predisposition records).
At a glance
- Classification: Cancer
- Causal gene: REST (GenCC Strong)
- Cohort genes: 1
- ClinVar variants: 58
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | Wilms tumor 6 |
| Mondo ID | MONDO:0014779 |
| OMIM | 616806 |
| UMLS | C3891301 |
| MedGen | 855962 |
| GARD | 0016162 |
| Is cancer (heuristic) | yes |
Also known as: Wilms tumor 6 · Wilms tumor 6; WT6 · Wilms tumor type 6 · Wilms tumour 6, susceptibility to · Wilms tumour 6; WT6 · Wilms tumour type 6 · WT6
Data availability: 58 ClinVar variants · 4 GenCC gene-disease records.
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › hereditary Wilms tumor › Wilms tumor 6
Related subtypes (6): Wilms tumor 1, Wilms tumor 2, Wilms tumor 3, Wilms tumor 4, Wilms tumor 5, Wilms tumor 7
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
58 retrieved; paginated sample, class counts are floors:
49 uncertain significance, 5 conflicting classifications of pathogenicity, 2 risk factor, 1 benign/likely benign, 1 pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 222002 | NM_005612.5(REST):c.831_832del (p.Cys278fs) | REST | Pathogenic | criteria provided, single submitter |
| 222003 | NM_005612.5(REST):c.773_776del (p.Val258fs) | REST | risk factor | no assertion criteria provided |
| 222004 | NM_005612.5(REST):c.965A>G (p.His322Arg) | REST | risk factor | no assertion criteria provided |
| 1019336 | NM_005612.5(REST):c.843C>T (p.Cys281=) | REST | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1135056 | NM_005612.5(REST):c.1902G>A (p.Met634Ile) | REST | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 2631848 | NM_005612.5(REST):c.2945G>A (p.Arg982His) | REST | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 3590636 | NM_005612.5(REST):c.458G>A (p.Ser153Asn) | REST | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 944664 | NM_005612.5(REST):c.3098A>G (p.His1033Arg) | REST | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1000502 | NM_005612.5(REST):c.2992G>A (p.Ala998Thr) | REST | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1013675 | NM_005612.5(REST):c.1747A>G (p.Thr583Ala) | REST | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1021123 | NM_005612.5(REST):c.2065C>T (p.Pro689Ser) | REST | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1025535 | NM_005612.5(REST):c.1639G>T (p.Val547Leu) | REST | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1047303 | NM_005612.5(REST):c.2068C>T (p.Pro690Ser) | REST | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1327569 | NM_005612.5(REST):c.2989A>G (p.Met997Val) | REST | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1347535 | NM_005612.5(REST):c.2050C>G (p.His684Asp) | REST | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1352070 | NM_005612.5(REST):c.2307A>G (p.Ile769Met) | REST | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1357352 | NM_005612.5(REST):c.2917A>G (p.Met973Val) | REST | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1418725 | NM_005612.5(REST):c.416A>G (p.Asp139Gly) | REST | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1446534 | NM_005612.5(REST):c.2780A>G (p.Asn927Ser) | REST | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1524176 | NM_005612.5(REST):c.2032G>T (p.Ala678Ser) | REST | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1691514 | NM_005612.5(REST):c.1881G>T (p.Gln627His) | REST | Uncertain significance | criteria provided, single submitter |
| 1931844 | NM_005612.5(REST):c.2753A>G (p.His918Arg) | REST | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 2170568 | NM_005612.5(REST):c.2741A>G (p.Asn914Ser) | REST | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 2174361 | NM_005612.5(REST):c.608C>G (p.Ser203Cys) | REST | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 2178538 | NM_005612.5(REST):c.3239A>G (p.Asn1080Ser) | REST | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 2181622 | NM_005612.5(REST):c.2053A>G (p.Met685Val) | REST | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 2444866 | NM_005612.5(REST):c.1882G>A (p.Val628Met) | REST | Uncertain significance | criteria provided, single submitter |
| 2444874 | NM_005612.5(REST):c.1701G>C (p.Glu567Asp) | REST | Uncertain significance | criteria provided, single submitter |
| 2444899 | NM_005612.5(REST):c.1583A>G (p.His528Arg) | REST | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 2444901 | NM_005612.5(REST):c.1367A>G (p.Asp456Gly) | REST | Uncertain significance | criteria provided, single submitter |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 10 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
Somatic driver evidence (intOGen + CIViC, cohort fanout)
| Gene | intOGen role | Cancer types | CIViC |
|---|---|---|---|
| REST | LoF | WT |
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| REST | Strong | Autosomal dominant | Wilms tumor 6 | 10 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| REST | Orphanet:2024 | Hereditary gingival fibromatosis |
| REST | Orphanet:654 | Nephroblastoma |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| REST | HGNC:9966 | ENSG00000084093 | Q13127 | RE1-silencing transcription factor | gencc,clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| REST | RE1-silencing transcription factor | Transcriptional repressor which binds neuron-restrictive silencer element (NRSE) and represses neuronal gene transcription in non-neuronal cells. |
Protein-family classification
Druggable: 0 · Difficult: 1 · Unknown: 0 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Transcription factor | 1 | 8.3× | 0.121 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| REST | Transcription factor | no | Znf_C2H2_type, Znf_C2H2_sf, Zinc_finger/UBP_domain |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| male germ line stem cell (sensu Vertebrata) in testis | 1 |
| mucosa of paranasal sinus | 1 |
| primordial germ cell in gonad | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| REST | 281 | ubiquitous | marker | primordial germ cell in gonad, mucosa of paranasal sinus, male germ line stem cell (sensu Vertebrata) in testis |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| REST | 2,499 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| REST | Q13127 | 3 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 5. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Regulation of NPAS4 gene transcription | 1 | 2284.0× | 0.002 | REST |
| NGF-stimulated transcription | 1 | 285.5× | 0.009 | REST |
| Regulation of PTEN gene transcription | 1 | 178.4× | 0.009 | REST |
| HDACs deacetylate histones | 1 | 120.2× | 0.009 | REST |
| Potential therapeutics for SARS | 1 | 114.2× | 0.009 | REST |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| negative regulation of dense core granule biogenesis | 1 | 16852.0× | 0.001 | REST |
| negative regulation of amniotic stem cell differentiation | 1 | 16852.0× | 0.001 | REST |
| modification of synaptic structure | 1 | 8426.0× | 0.001 | REST |
| negative regulation of mesenchymal stem cell differentiation | 1 | 8426.0× | 0.001 | REST |
| negative regulation of aldosterone biosynthetic process | 1 | 4213.0× | 0.002 | REST |
| negative regulation of cortisol biosynthetic process | 1 | 4213.0× | 0.002 | REST |
| negative regulation of calcium ion-dependent exocytosis | 1 | 1872.4× | 0.003 | REST |
| cardiac muscle cell myoblast differentiation | 1 | 1404.3× | 0.003 | REST |
| host-mediated suppression of viral transcription | 1 | 1296.3× | 0.003 | REST |
| regulation of osteoblast differentiation | 1 | 1296.3× | 0.003 | REST |
| cellular response to electrical stimulus | 1 | 1296.3× | 0.003 | REST |
| nervous system process | 1 | 1203.7× | 0.003 | REST |
| positive regulation of programmed cell death | 1 | 1123.5× | 0.003 | REST |
| detection of mechanical stimulus involved in sensory perception of sound | 1 | 936.2× | 0.003 | REST |
| cellular response to stress | 1 | 842.6× | 0.003 | REST |
| auditory receptor cell stereocilium organization | 1 | 842.6× | 0.003 | REST |
| neuronal stem cell population maintenance | 1 | 674.1× | 0.003 | REST |
| negative regulation of neurogenesis | 1 | 624.1× | 0.003 | REST |
| cellular response to glucocorticoid stimulus | 1 | 624.1× | 0.003 | REST |
| negative regulation of miRNA transcription | 1 | 624.1× | 0.003 | REST |
| negative regulation of insulin secretion | 1 | 495.6× | 0.004 | REST |
| positive regulation of stem cell population maintenance | 1 | 343.9× | 0.005 | REST |
| neuromuscular process controlling balance | 1 | 330.4× | 0.005 | REST |
| negative regulation of neuron differentiation | 1 | 271.8× | 0.006 | REST |
| response to ischemia | 1 | 251.5× | 0.006 | REST |
| somatic stem cell population maintenance | 1 | 247.8× | 0.006 | REST |
| regulation of alternative mRNA splicing, via spliceosome | 1 | 244.2× | 0.006 | REST |
| hematopoietic progenitor cell differentiation | 1 | 237.3× | 0.006 | REST |
| positive regulation of neuron differentiation | 1 | 198.3× | 0.007 | REST |
| response to hypoxia | 1 | 95.8× | 0.013 | REST |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1
Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| REST | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Drug repurposing candidates
0 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 1 | REST |
Undrugged target profiles
1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| REST | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: REST